Evidence map›Paper›PMID 12684537›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2003

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

M C Strain, H F Günthard, D V Havlir, C C Ignacio, D M Smith, A J Leigh-Brown, T R Macaranas, R Y Lam, O A Daly, M Fischer and 6 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. HIV-1 latency: From acquaintance to confidant.Journal of virus eradication · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR.Antimicrobial agents and chemotherapy · 2023
    Article
  15. Review
  16. TCR-mimic bispecific antibodies to target the HIV-1 reservoir.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

M C StrainDepartment of Medicine and Pathology, University of California at San Diego, La Jolla, CA 90293, USA.
H F Günthard
D V Havlir
C C Ignacio
D M Smith
A J Leigh-Brown
T R Macaranas
R Y Lam
O A Daly
M Fischer
M Opravil
H Levine
L Bacheler
C A Spina
D D Richman
J K Wong

Funding

WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mary Kathleen Lewinski · 1994 to 2026
$78.4M
WOMEN'S HEALTH AGENDAU01AI027670 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 1988 to 2006
$13.7M
ANTIVIRAL RESISTANCE IN AIDSR37AI029164 · NIAID · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI RICHMAN, DOUGLAS D · 1994 to 2004
$2.0M
Therapeutic Strategies for HIV DiseaseK24AI051982 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2002 to 2012
$1.3M
IN VIVO HIV LATENCY REVEALED BY POTENT ANTIVIRAL THERAPYR01AI043752 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI WONG, JOSEPH K. · 1999 to 2002
$759k
MECHANISMS OF RESISTANCE IN CLINICAL ISOLATES OF HIVR01AI029164 · NIAID · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI RICHMAN, DOUGLAS D · 1989 to 1993
–
NIAID NIH HHS AI27670NIAID NIH HHS AI29164NIAID NIH HHS AI36214NIAID NIH HHS AI38858NIAID NIH HHS AI43752NIAID NIH HHS AI51982NIAID NIH HHS K24 AI051982NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI043752NIAID NIH HHS R37 AI029164NIAID NIH HHS U01 AI027670NIAID NIH HHS U01 AI038858
6 · The paper itself

Abstract

Viral replication and latently infected cellular reservoirs persist in HIV-infected patients achieving undetectable plasma virus levels with potent antiretroviral therapy. We exploited a predictable drug resistance mutation in the HIV reverse transcriptase to label and track cells infected during defined intervals of treatment and to identify cells replenished by ongoing replication. Decay rates of subsets of latently HIV-infected cells paradoxically decreased with time since establishment, reflecting heterogeneous lymphocyte activation and clearance. Residual low-level replication can replenish cellular reservoirs; however, it does not account for prolonged clearance rates in patients without detectable viremia. In patients receiving potent antiretroviral therapy, the latent pool has a heterogeneous and dynamic composition that comprises a progressively increasing proportion of stable lymphocytes. Eradication will not be achieved with complete inhibition of viral replication alone.

Indexed as

Antiretroviral Therapy, Highly ActiveCell SurvivalDNA, ViralHIV-1HIV InfectionsHIV Reverse TranscriptaseHumansLymphocytesPoint MutationTime FactorsViremiaVirus ReplicationDNA, ViralHIV Reverse Transcriptase

Identifiers

PMID12684537
PMCPMC153639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.